Unknown

Dataset Information

0

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.


ABSTRACT: The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence Score-tested through Clalit Health Services from 1/2006 through 12/2011 (N?=?709). Medical records were reviewed to verify treatments/recurrences/survival. Median follow-up, 5.9 years; median age, 62 years; 53.9% grade 2; 69.8% tumors???2?cm; 84.5% invasive ductal carcinoma; 42.0% N1mi, and 37.2%/15.5%/5.2% with 1/2/3 positive nodes; 53.4% Recurrence Score?n?=?27) and 2.9% in chemotherapy-untreated patients (n?=?352); P?=?0.245. In Recurrence Score 18-30, recurrence rate in chemotherapy-treated patients (n?=?102) was significantly lower than in untreated patients (n?=?156) (1.0% vs. 9.7% P?=?0.019); in Recurrence Score???25 (the RxPONDER study cutoff), recurrence rate was 2.3% in chemotherapy-treated (n?=?89) and 4.4% in chemotherapy-untreated patients (n?=?488); P?=?0.521. In conclusion, our findings support using endocrine therapy alone in ER+ HER2-negative breast cancer patients with micrometastases/1-3 positive nodes and Recurrence Score?

SUBMITTER: Stemmer SM 

PROVIDER: S-EPMC5591314 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.

Stemmer Salomon M SM   Steiner Mariana M   Rizel Shulamith S   Geffen David B DB   Nisenbaum Bella B   Peretz Tamar T   Soussan-Gutman Lior L   Bareket-Samish Avital A   Isaacs Kevin K   Rosengarten Ora O   Fried Georgeta G   McCullough Debbie D   Svedman Christer C   Shak Steven S   Liebermann Nicky N   Ben-Baruch Noa N  

NPJ breast cancer 20170908


The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence Score-tested through Clalit Health Services from 1/2006 through 12/2011 (<i>N</i> = 709). Medical records were reviewed to verify treatments/recurrences/survival. Median follow-up, 5.9 years; median age, 62 years; 53.9% grade 2; 69.8% tumors ≤ 2 cm; 84  ...[more]

Similar Datasets

| S-EPMC5591181 | biostudies-literature
| S-EPMC5721938 | biostudies-literature
| S-EPMC7048163 | biostudies-literature
| S-EPMC5648884 | biostudies-literature
| S-EPMC4964078 | biostudies-literature
| S-EPMC6998376 | biostudies-literature
| S-EPMC4076639 | biostudies-literature
| S-EPMC5695596 | biostudies-other
| S-EPMC8394098 | biostudies-literature
| S-EPMC6221170 | biostudies-other